Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrences
Bitget2026/10/05 15:27Guardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating its Reveal blood test in resected stage II-III melanoma. The paper has already been published in Cancer Research Communications. Findings supported the test’s ability to flag patients at higher recurrence risk and to detect relapse earlier than standard clinical identification. Results also indicated strong accuracy in patients who remained recurrence-free, supporting potential use in post-surgery surveillance decisions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051127BIZWIRE_USPR_____20261002_BW257126) on October 05, 2026, and is solely responsible for the information contained therein.
- Guardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating its Reveal blood test in resected stage II-III melanoma.
- The paper has already been published in Cancer Research Communications.
- Findings supported the test’s ability to flag patients at higher recurrence risk and to detect relapse earlier than standard clinical identification.
- Results also indicated strong accuracy in patients who remained recurrence-free, supporting potential use in post-surgery surveillance decisions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
